Global Dermatitis API Manufacturers, Marketed and Phase III Drugs Landscape Report 2017-2018 - Research and Markets

Research and Markets has announced the addition of the "Dermatitis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" drug pipelines to their offering.

Dermatitis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe.

A key objective of the Dermatitis Report is to understand the market and pipeline status of the drugs around the Dermatitis to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline strategies. The Report provides the historical and forecasted sales of the drugs till 2018.

The Dermatitis Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Dermatitis.

While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Key Topics Covered:

1. Indication Overview

2. Market Drugs Landscape

3. Global API Manufacturers Assessment

4. Phase III Drugs Landscape

5. Drugs Market Data and Forecasted Sales Figure-2018

6. Marketed Drugs for Dermatitis

7. Phase III Drugs for Dermatitis

8. Discontinued Drugs for Dermatitis

9. Appendix

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/ccnqzj/dermatitis

Contacts:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs, Dermatological Drugs

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.